Identification of Phenylphthalazinones as a New Class of Leishmania infantum Inhibitors

Maarten Sijm, Erik de Heuvel, An Matheeussen, Guy Caljon, Louis Maes, Geert Jan Sterk, Iwan J.P. de Esch, Rob Leurs*

*Corresponding author for this work

Research output: Contribution to JournalArticle


Leishmaniasis is a neglected parasitic disease caused by over 20 different Leishmania species. Current treatments often rely on harsh regimes of pentavalent antimonials such as sodium stibogluconate, while more recent drugs suffer other shortcomings such as low stability and rapid emergence of treatment failure, amongst others. Furthermore, the effectiveness of drugs varies depending on the infecting Leishmania species, thus there is an urgent need for new and effective anti-leishmanial drugs. Screening of an in-house compound library identified the hexahydrophthalazinone NPD-2942 as a low micromolar hit with a pIC50 of 5.8 against L. infantum and a pIC50 of 4.6 for cytotoxicity against human MRC-5 fibroblasts. To derive structure–activity relationships, we modified the cyclohexyl ring of the hexahydrophthalazinone scaffold and 1,2,3-triazoles were attempted as replacement for the pyrazole ring, amongst others. Ultimately, the 2,3-pyrazole-substituted hexahydrophthalazinone NPD-1289 was identified as the most potent analogue in this series with a pIC50 of 6.3, although some cytotoxicity toward MRC-5 cells (pIC50=5.1) was recorded as well. Replacement of the unsubstituted 2,3-pyrazole with 1,2,3-triazoles led to compounds with lower anti-leishmanial activity. The current scaffold is a valuable new starting point for optimization toward novel anti-leishmanial drugs.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
Issue number2
Publication statusE-pub ahead of print - 22 Nov 2019



  • antiprotozoal agents
  • leishmania infantum
  • leishmaniasis
  • phenylphthalazinones
  • structure-activity relationships

Cite this